PMID- 8859934
OWN - NLM
STAT- MEDLINE
DCOM- 19970410
LR  - 20190724
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 27
IP  - 5
DP  - 1996 May
TI  - Effect of mibefradil on left ventricular diastolic function in patients with 
      congestive heart failure.
PG  - 652-6
AB  - Calcium antagonists have antihypertensive and antianginal properties. In heart 
      failure, however, their use can be hazardous, as systolic function can 
      deteriorate. This may not be true of the new calcium antagonist mibefradil, which 
      has a new chemical structure. Calcium antagonists may also be beneficial for 
      diastolic left ventricular function in coronary artery disease. To investigate 
      the possible effects of mibefradil on diastolic left ventricular function, we 
      performed the present study as a multicenter, double-blind,placebo-controlled, 
      multiple-dose safety trial. Fifteen patients with New York Heart Association 
      (NYHA) class II or III for dyspnea and depressed ejection fraction (<40%) due to 
      a previous myocardial infarction were investigated. The measured nuclear 
      angiographic parameters included ejection fraction (EF), peak ejection rate 
      (PER), and peak filling rate (PFR). Systolic and diastolic blood pressure (SBP, 
      DBP) and heart rate (HR) were also obtained. Group I (5 patients) received 
      placebo medication; group IIA (6 patients) received mibefradil 6.25, 12.5, or 25 
      mg/day; and group IIB (4 patients) received mibefradil 50 or 100 mg/day. 
      Measurements were made before and after the first dose and after 1 week of 
      treatment before and after the final dose. Mibefradil clearly decreased HR 
      (repeated-measures analysis of variance p < 0.05). No statistically significant 
      effects of mibefradil were noted on SBP or DBP or on systolic and diastolic left 
      ventricular function. In our study conditions, mibefradil caused no worsening of 
      systolic function and preserved diastolic function in short-term treatment of 
      patients with decreased EF and heart failure.
FAU - Muntinga, H J
AU  - Muntinga HJ
AD  - Department of Cardiology, Martini Hospital, Groningen, The Netherlands.
FAU - van der Vring, J A
AU  - van der Vring JA
FAU - Niemeyer, M G
AU  - Niemeyer MG
FAU - van den Berg, F
AU  - van den Berg F
FAU - Knol, H R
AU  - Knol HR
FAU - Bernink, P J
AU  - Bernink PJ
FAU - van der Wall, E E
AU  - van der Wall EE
FAU - Blanksma, P K
AU  - Blanksma PK
FAU - Lie, K I
AU  - Lie KI
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Benzimidazoles)
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Tetrahydronaphthalenes)
RN  - 27B90X776A (Mibefradil)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Benzimidazoles/*pharmacology
MH  - Calcium Channel Blockers/*pharmacology
MH  - Diastole/*drug effects
MH  - Double-Blind Method
MH  - Female
MH  - Heart Failure/*physiopathology
MH  - Humans
MH  - Male
MH  - Mibefradil
MH  - Middle Aged
MH  - Tetrahydronaphthalenes/*pharmacology
MH  - Ventricular Function, Left/*drug effects
EDAT- 1996/05/01 00:00
MHDA- 1996/05/01 00:01
CRDT- 1996/05/01 00:00
PHST- 1996/05/01 00:00 [pubmed]
PHST- 1996/05/01 00:01 [medline]
PHST- 1996/05/01 00:00 [entrez]
AID - 10.1097/00005344-199605000-00006 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 1996 May;27(5):652-6. doi: 
      10.1097/00005344-199605000-00006.